Welcome to Merz North America

Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the US. Our products are distributed through two divisions: Aesthetics and Neurosciences.


Merz Encourages Women to Smash through Labels and Judgment with Disruptive New DTC Campaign for XEOMIN® (incobotulinumtoxinA)

Merz Americas announced today the launch of a new advertising campaign for XEOMIN® (incobotulinumtoxinA) called “Later Haters,” which calls for women to “X out” judgment, stop apologizing for caring about how they look and put an end to feeling guilty about their self-care routines. XEOMIN is the latest botulinum toxin type A approved by the U.S. Food and Drug Administration (FDA) to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.

Read More

Merz presents data confirming the long-term efficacy and safety of Xeomin® (incobotulinumtoxina) for sialorrhea

Merz today announced long-term results from a Phase 3 extension study of XEOMIN® (incobotulinumtoxinA) for the treatment of adults with chronic sialorrhea, also known as excessive drooling. Results were presented at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly being held October 25-28 in Orlando, FL.

Read More

Merz Named “Top Aesthetics Company” by Aesthetic Everything® for Second Year in a Row

For the second year in a row, Merz has been recognized as the “Top Aesthetics Company” by Aesthetic Everything® and Bob Rhatigan has been named the “Top Aesthetics CEO.” As part of the annual Aesthetic and Cosmetic Medicine Awards, Merz executives and products were also recognized with 14 additional award wins – 16 total wins overall.

Read More